The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.
|Slideshows|April 18, 2018
6 New Drugs for Neurologists
Author(s)Susan Kweskin
Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.
Advertisement
Newly approved treatments for several neurologic disorders-including various types of pain, generalized myasthenia gravis, and Parkinson Disease-will be topics of discussion at AAN 2018. Here’s a brief overview of those medications FDA approved within the past 6 months.
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.
Here's some of what is coming soon to NeurologyLive® this week.
Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of neurology!
Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding Cemdisiran's Mechanism of Action in Myasthenia Gravis
2
Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy
3
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
4
Insights on the Updated 2026 AHA/ASA Stroke Rehabilitation Guidelines
5